(Q39319803)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Paolo Fagone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Marco Donia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Katia Mangano

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Santa Mammana

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

James A. McCubrey

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Ferdinando Nicoletti

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Ferdinando Nicoletti

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Cinzia Quattrocchi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Marinella Coco

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

26 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

Basic and Clinical Pharmacology and Toxicology

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

63-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

Considerations in sirolimus use in the early and late post-transplant periods

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

mTOR pathway and mTOR inhibitors as agents for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Key factors in mTOR regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Potential use of rapamycin in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

The mTOR pathway: a new target in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Rapamycin: something old, something new, sometimes borrowed and now renewed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Pilot study of rapamycin in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Detection of dead cells and measurement of cell killing by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Measurement of apoptosis and other forms of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Determination of lymphocyte division by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Heterogeneous cell response to topotecan in a CFSE-based proliferation test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Antiproliferative activity of cisplatin detected by CFSE in p53-proficient and p53-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

mTOR: the mammalian target of replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00923.X

10.1111/J.1742-7843.2012.00923.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json

release_rib54ofhwjb53kpk3lubs2x35i

7 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rib54ofhwjb53kpk3lubs2x35i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762560%20AND%20SRC:MED&resulttype=core&format=json